229 related articles for article (PubMed ID: 25323305)
21. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
Dusheiko G
Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
[TBL] [Abstract][Full Text] [Related]
22. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B.
Xu XW; Chen YG
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):350-9. PubMed ID: 16911930
[TBL] [Abstract][Full Text] [Related]
23. Current developments in nucleoside/nucleotide analogues for hepatitis B.
Lo AO; Wong GL
Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):607-22. PubMed ID: 24787673
[TBL] [Abstract][Full Text] [Related]
24. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors.
Qiu LP; Chen L; Chen KP
Fundam Clin Pharmacol; 2014 Aug; 28(4):364-81. PubMed ID: 24118072
[TBL] [Abstract][Full Text] [Related]
25. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.
Viganò M; Invernizzi F; Grossi G; Lampertico P
Aliment Pharmacol Ther; 2016 Oct; 44(7):653-61. PubMed ID: 27528410
[TBL] [Abstract][Full Text] [Related]
26. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China.
Qi X; Wang JY; Mao RC; Zhang JM
J Viral Hepat; 2015 Jan; 22(1):46-54. PubMed ID: 25402626
[TBL] [Abstract][Full Text] [Related]
27. Treatment of HBeAg-positive patients with nucleos/tide analogues.
Coffin CS; Lee SS
Liver Int; 2009 Jan; 29 Suppl 1():116-24. PubMed ID: 19207974
[TBL] [Abstract][Full Text] [Related]
28. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
[TBL] [Abstract][Full Text] [Related]
29. Chronic Hepatitis B Infection: A Review.
Tang LSY; Covert E; Wilson E; Kottilil S
JAMA; 2018 May; 319(17):1802-1813. PubMed ID: 29715359
[TBL] [Abstract][Full Text] [Related]
30. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Papatheodoridis GV; Dimou E; Dimakopoulos K; Manolakopoulos S; Rapti I; Kitis G; Tzourmakliotis D; Manesis E; Hadziyannis SJ
Hepatology; 2005 Jul; 42(1):121-9. PubMed ID: 15962291
[TBL] [Abstract][Full Text] [Related]
31. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Petersen J; Buti M
Expert Rev Gastroenterol Hepatol; 2012 Dec; 6(6):683-93; quiz 694. PubMed ID: 23237254
[TBL] [Abstract][Full Text] [Related]
32. Chronic hepatitis B--who should be treated?
Coffin CS; Lee SS
MedGenMed; 2006 Mar; 8(1):75. PubMed ID: 16915205
[TBL] [Abstract][Full Text] [Related]
33. Management of chronic hepatitis B infection.
Sundaram V; Kowdley K
BMJ; 2015 Oct; 351():h4263. PubMed ID: 26491030
[TBL] [Abstract][Full Text] [Related]
34. Emerging pipeline drugs for hepatitis B infection.
Cox N; Tillmann H
Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
[TBL] [Abstract][Full Text] [Related]
35. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
Lau GK
Liver Int; 2010 Apr; 30(4):512-20. PubMed ID: 20102511
[TBL] [Abstract][Full Text] [Related]
36. Prevention and management of drug resistant hepatitis B virus infections.
Wang C; Fan R; Sun J; Hou J
J Gastroenterol Hepatol; 2012 Sep; 27(9):1432-40. PubMed ID: 22694205
[TBL] [Abstract][Full Text] [Related]
37. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
38. Systematic review: combination therapies for treatment-naïve chronic hepatitis B.
Kumar M; Sarin SK
Aliment Pharmacol Ther; 2008 Jun; 27(12):1187-209. PubMed ID: 18373730
[TBL] [Abstract][Full Text] [Related]
39. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
40. Monotherapy versus combination therapy for the treatment of chronic hepatitis B.
Carey I; Harrison PM
Expert Opin Investig Drugs; 2009 Nov; 18(11):1655-66. PubMed ID: 19852566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
